---
document_datetime: 2025-12-02 06:51:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/firdapse.html
document_name: firdapse.html
version: success
processing_time: 0.1128535
conversion_datetime: 2025-12-28 08:47:58.60277
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Firdapse (previously Zenas)

[RSS](/en/individual-human-medicine.xml/66007)

##### Authorised

This medicine is authorised for use in the European Union

amifampridine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Firdapse](#more-information-on-firdapse-584)
- [More information on Firdapse (previously Zenas)](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Firdapse. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Firdapse.

Expand section

Collapse section

## What is Firdapse?

Firdapse is a medicine that contains the active substance amifampridine. It is available as tablets (10 mg).

## What is Firdapse used for?

Firdapse is used to treat the symptoms of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a disease in which patients have muscle weakness because of a failure of the nerves to transmit electrical impulses to the muscles.

Because the number of patients with LEMS is low, the disease is considered 'rare', and Firdapse was designated an 'orphan medicine' (a medicine used in rare diseases) on 18 December 2002.

The medicine can only be obtained with a prescription.

## How is Firdapse used?

Treatment with Firdapse should only be started under the supervision of a doctor experienced in treating LEMS.

The recommended starting dose of Firdapse is 15 mg per day, which can be increased by 5 mg every four to five days up to a maximum of 60 mg per day. Firdapse is taken in divided doses, three or four times a day, and a single dose should not be more than 20 mg. Firdapse should be taken with food.

## How does Firdapse work?

For muscles to contract, nerves have to transmit electrical impulses to the muscles through a chemical messenger called acetylcholine. Acetylcholine is released from the nerve endings during a period of 'depolarisation'.

The active substance in Firdapse, amifampridine, is a potassium channel blocker, which prevents charged potassium particles from leaving the nerve cells. This prolongs the period of depolarisation, allowing more time for the nerves to release acetylcholine and so stimulate the muscles to contract.

## How has Firdapse been studied?

Because amifampridine-containing medicines have been used in the European Union (EU) for over 20 years, the company presented the results of studies from the scientific literature on amifampridine to support the use of Firdapse. In two published studies involving a total of 38 adults with LEMS, amifampridine was compared with placebo (a dummy treatment). The main measures of effectiveness were based on the rating of how well the muscles worked using a scoring system, either the neurological disability score (NDS) or the quantitative myasthenia gravis (QMG) score. Patients with lower NDS or QMG scores have better muscle function. Another study combined data from the two published studies and looked at compound muscle action potential (CMAP). CMAP is a measure of electrical activity in muscles. Additionally, the effect of Firdapse on the QT interval (the electrical activity of the heart) was investigated.

## What benefit has Firdapse shown during the studies?

Firdapse was more effective than placebo at treating patients with LEMS. In one study, the NDS was reduced from 40 to 22 points in patients taking Firdapse compared with a drop to 35 points in patients taking placebo. The other study showed a reduction in the QMG score of 2 points in patients taking Firdapse compared with a rise of 0.25 points in patients taking placebo. In the third combined study, patients taking Firdapse had better improvements in CMAP than patients taking placebo. In the QT study, amifampridine was observed to have no effects on the activity of the heart, as shown by the electrocardiograms of healthy volunteers taking part in this study.

## What is the risk associated with Firdapse?

The most common side effects reported with Firdapse are paraesthesia (unusual sensations like pins and needles) and gastro-intestinal disorders such as epigastralgia (pain around the upper part of the stomach), diarrhoea, nausea (feeling sick) and abdominal pain (stomach ache).

Firdapse must not be used in patients who have epilepsy or in patients with uncontrolled asthma or congenital QT syndromes (disruption of the heartbeat). It must not be used with sultopride (an antipsychotic medicine), or medicines known to cause QTc prolongation (an alteration of the electrical activity of the heart). It must also not be used with medicines that have a narrow therapeutic window. A medicine with a narrow therapeutic window can easily cause side effects if given at a dose a little higher than the recommended dose.

For the full list of all side effects and restrictions with Firdapse, see the package leaflet.

## Why has Firdapse been approved?

The CHMP decided that Firdapse's benefits are greater than its risks and recommended that it be given marketing authorisation.

Firdapse has been authorised under 'exceptional circumstances'. This means that because the disease is rare, it has not been possible to obtain complete information about Firdapse. Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.

## What information is still awaited for Firdapse?

The company that makes Firdapse will provide further data from studies on cancer in experimental models.

## What measures are being taken to ensure the safe and effective use of Firdapse?

A risk management plan has been developed to ensure that Firdapse is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Firdapse, including the appropriate precautions to be followed by healthcare professionals and patients.

Additionally, the company that markets Firdapse has been required to set up a patient registry for patients with LEMS. The company will ensure that all healthcare professionals who are expected to use the medicine are provided with information on how to enter their patients in the registry.

## Other information about Firdapse

The European Commission granted a marketing authorisation valid throughout the EU for Zenas on 23 December 2009. The name of the medicine was changed to Firdapse on 28 January 2010.

For more information about treatment with Firdapse, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Firdapse : EPAR - Summary for the public

English (EN) (155.44 KB - PDF)

**First published:** 28/01/2010

**Last updated:** 19/08/2014

[View](/en/documents/overview/firdapse-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-776)

български (BG) (218.57 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/bg/documents/overview/firdapse-epar-summary-public_bg.pdf)

español (ES) (182.79 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/es/documents/overview/firdapse-epar-summary-public_es.pdf)

čeština (CS) (191.7 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/cs/documents/overview/firdapse-epar-summary-public_cs.pdf)

dansk (DA) (185.6 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/da/documents/overview/firdapse-epar-summary-public_da.pdf)

Deutsch (DE) (164.53 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/de/documents/overview/firdapse-epar-summary-public_de.pdf)

eesti keel (ET) (177.75 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/et/documents/overview/firdapse-epar-summary-public_et.pdf)

ελληνικά (EL) (208.8 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/el/documents/overview/firdapse-epar-summary-public_el.pdf)

français (FR) (166.7 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/fr/documents/overview/firdapse-epar-summary-public_fr.pdf)

hrvatski (HR) (183.12 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/hr/documents/overview/firdapse-epar-summary-public_hr.pdf)

italiano (IT) (179.86 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/it/documents/overview/firdapse-epar-summary-public_it.pdf)

latviešu valoda (LV) (219.42 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/lv/documents/overview/firdapse-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (206.69 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/lt/documents/overview/firdapse-epar-summary-public_lt.pdf)

magyar (HU) (209.42 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/hu/documents/overview/firdapse-epar-summary-public_hu.pdf)

Malti (MT) (170.61 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/mt/documents/overview/firdapse-epar-summary-public_mt.pdf)

Nederlands (NL) (166.45 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/nl/documents/overview/firdapse-epar-summary-public_nl.pdf)

polski (PL) (211.02 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/pl/documents/overview/firdapse-epar-summary-public_pl.pdf)

português (PT) (160.23 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/pt/documents/overview/firdapse-epar-summary-public_pt.pdf)

română (RO) (147.77 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/ro/documents/overview/firdapse-epar-summary-public_ro.pdf)

slovenčina (SK) (175.76 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/sk/documents/overview/firdapse-epar-summary-public_sk.pdf)

slovenščina (SL) (181.34 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/sl/documents/overview/firdapse-epar-summary-public_sl.pdf)

Suomi (FI) (154.45 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/fi/documents/overview/firdapse-epar-summary-public_fi.pdf)

svenska (SV) (176.11 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

19/08/2014

[View](/sv/documents/overview/firdapse-epar-summary-public_sv.pdf)

Firdapse : EPAR - Risk management plan

English (EN) (28.11 MB - PDF)

**First published:** 18/12/2024

[View](/en/documents/rmp/firdapse-epar-risk-management-plan_en.pdf)

## Product information

Firdapse : EPAR - Product Information

English (EN) (404.54 KB - PDF)

**First published:** 28/01/2010

**Last updated:** 25/05/2022

[View](/en/documents/product-information/firdapse-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-259)

български (BG) (584.11 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/bg/documents/product-information/firdapse-epar-product-information_bg.pdf)

español (ES) (450.28 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/es/documents/product-information/firdapse-epar-product-information_es.pdf)

čeština (CS) (538.57 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/cs/documents/product-information/firdapse-epar-product-information_cs.pdf)

dansk (DA) (399.36 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/da/documents/product-information/firdapse-epar-product-information_da.pdf)

Deutsch (DE) (344.77 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/de/documents/product-information/firdapse-epar-product-information_de.pdf)

eesti keel (ET) (410.06 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/et/documents/product-information/firdapse-epar-product-information_et.pdf)

ελληνικά (EL) (475.65 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/el/documents/product-information/firdapse-epar-product-information_el.pdf)

français (FR) (381.99 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/fr/documents/product-information/firdapse-epar-product-information_fr.pdf)

hrvatski (HR) (447.26 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/hr/documents/product-information/firdapse-epar-product-information_hr.pdf)

íslenska (IS) (263.16 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/is/documents/product-information/firdapse-epar-product-information_is.pdf)

italiano (IT) (436.51 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/it/documents/product-information/firdapse-epar-product-information_it.pdf)

latviešu valoda (LV) (446.64 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/lv/documents/product-information/firdapse-epar-product-information_lv.pdf)

lietuvių kalba (LT) (448.73 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/lt/documents/product-information/firdapse-epar-product-information_lt.pdf)

magyar (HU) (448.9 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/hu/documents/product-information/firdapse-epar-product-information_hu.pdf)

Malti (MT) (487.51 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/mt/documents/product-information/firdapse-epar-product-information_mt.pdf)

Nederlands (NL) (347.95 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/nl/documents/product-information/firdapse-epar-product-information_nl.pdf)

norsk (NO) (372.08 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/no/documents/product-information/firdapse-epar-product-information_no.pdf)

polski (PL) (500.32 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/pl/documents/product-information/firdapse-epar-product-information_pl.pdf)

português (PT) (395.02 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/pt/documents/product-information/firdapse-epar-product-information_pt.pdf)

română (RO) (475.32 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/ro/documents/product-information/firdapse-epar-product-information_ro.pdf)

slovenčina (SK) (324.34 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/sk/documents/product-information/firdapse-epar-product-information_sk.pdf)

slovenščina (SL) (466.74 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/sl/documents/product-information/firdapse-epar-product-information_sl.pdf)

Suomi (FI) (346.54 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/fi/documents/product-information/firdapse-epar-product-information_fi.pdf)

svenska (SV) (366.97 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

25/05/2022

[View](/sv/documents/product-information/firdapse-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** S/0071 22/07/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Firdapse : EPAR - All Authorised presentations

English (EN) (17 KB - PDF)

**First published:** 28/01/2010

**Last updated:** 11/02/2010

[View](/en/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-676)

български (BG) (46.84 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/bg/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.99 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/es/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_es.pdf)

čeština (CS) (31.46 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/cs/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (22.1 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/da/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (16.96 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/de/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (34.92 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/et/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (38.99 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/el/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_el.pdf)

français (FR) (16.97 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/fr/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (37.48 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/hr/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (19.27 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/is/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_is.pdf)

italiano (IT) (16.93 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/it/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (42.07 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/lv/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (35.69 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/lt/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (33.65 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/hu/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (33.88 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/mt/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.27 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/nl/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.92 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/no/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_no.pdf)

polski (PL) (28.82 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/pl/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_pl.pdf)

português (PT) (16.92 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/pt/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.54 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/ro/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (24.94 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/sk/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.49 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/sl/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.49 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/fi/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.75 KB - PDF)

**First published:**

28/01/2010

**Last updated:**

11/02/2010

[View](/sv/documents/all-authorised-presentations/firdapse-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Firdapse (previously Zenas) Active substance amifampridine International non-proprietary name (INN) or common name amifampridine Therapeutic area (MeSH) Lambert-Eaton Myasthenic Syndrome Anatomical therapeutic chemical (ATC) code N07XX05

### Pharmacotherapeutic group

Other nervous system drugs

### Therapeutic indication

Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

## Authorisation details

EMA product number EMEA/H/C/001032

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

SERB SA

Avenue Louise 480

Opinion adopted 22/10/2009 Marketing authorisation issued 23/12/2009 Revision 22

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Firdapse : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (254.08 KB - PDF)

**First published:** 10/02/2010

**Last updated:** 24/02/2022

[View](/en/documents/procedural-steps-after/firdapse-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Firdapse : EPAR - Public assessment report

English (EN) (531.64 KB - PDF)

**First published:** 28/01/2010

**Last updated:** 28/01/2010

[View](/en/documents/assessment-report/firdapse-epar-public-assessment-report_en.pdf)

#### More information on Firdapse

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-02-124) on 18 December 2002. Firdapse was withdrawn from the Community register of orphan medicinal products in December 2019 at the end of the 10-year period of market exclusivity.

#### More information on Firdapse (previously Zenas)

- [Lambert-Eaton Myasthenic Syndrome (LEMS) Registry (LEMS-01) - post-authorisation study](https://catalogues.ema.europa.eu/study/39278)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/12/2024

## Share this page

[Back to top](#main-content)